ATE162947T1 - Neue verwendungen für il-10 - Google Patents

Neue verwendungen für il-10

Info

Publication number
ATE162947T1
ATE162947T1 AT93920050T AT93920050T ATE162947T1 AT E162947 T1 ATE162947 T1 AT E162947T1 AT 93920050 T AT93920050 T AT 93920050T AT 93920050 T AT93920050 T AT 93920050T AT E162947 T1 ATE162947 T1 AT E162947T1
Authority
AT
Austria
Prior art keywords
new uses
alone
optionally
manufacture
combination
Prior art date
Application number
AT93920050T
Other languages
English (en)
Inventor
Robert Coffman
Vries Jan E De
Waal Malefyt Rene De
Fiona Powrie
Donna Rennick
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/932,900 external-priority patent/US5368854A/en
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE162947T1 publication Critical patent/ATE162947T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
AT93920050T 1992-08-20 1993-08-18 Neue verwendungen für il-10 ATE162947T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/932,900 US5368854A (en) 1992-08-20 1992-08-20 Use of IL-10 to treat inflammatory bowel disease
US93341992A 1992-08-21 1992-08-21
US93395092A 1992-08-21 1992-08-21
US93346292A 1992-08-21 1992-08-21

Publications (1)

Publication Number Publication Date
ATE162947T1 true ATE162947T1 (de) 1998-02-15

Family

ID=27506019

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93920050T ATE162947T1 (de) 1992-08-20 1993-08-18 Neue verwendungen für il-10

Country Status (23)

Country Link
EP (2) EP0801951A3 (de)
JP (1) JP3494647B2 (de)
KR (1) KR0170037B1 (de)
CN (1) CN1090204A (de)
AT (1) ATE162947T1 (de)
AU (1) AU680628B2 (de)
CA (1) CA2142861C (de)
CZ (1) CZ283488B6 (de)
DE (1) DE69316921T2 (de)
DK (1) DK0671933T3 (de)
ES (1) ES2111769T3 (de)
FI (1) FI950697L (de)
GR (1) GR3026635T3 (de)
HK (1) HK1004326A1 (de)
HU (1) HU220103B (de)
IL (1) IL106725A (de)
MX (1) MX9305054A (de)
MY (1) MY111402A (de)
PL (1) PL307566A1 (de)
RU (1) RU2120802C1 (de)
SK (1) SK21195A3 (de)
TW (1) TW243415B (de)
WO (1) WO1994004180A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017773A2 (en) * 1993-02-01 1994-08-18 Université Libre de Bruxelles Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
AU686816B2 (en) * 1994-07-05 1998-02-12 Steeno Research Group A/S Immunomodulators
DE69534265T2 (de) * 1994-12-12 2006-05-04 Beth Israel Deaconess Medical Center, Inc., Boston Chimäre zytokine und ihre verwendung
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
EP0756871A1 (de) * 1995-08-01 1997-02-05 Institut Pasteur Verwendung von pharmazeutischen Zusammensetzungen die eine wirksame Dosierung von Interleukin-10 enthalten, einem Analogen und/oder einem Agonisten für Interleukin-10
EP0901375A1 (de) * 1996-04-17 1999-03-17 Patrick Thomas Prendergast Dhea-kombinationstherapie
WO1998027997A1 (en) * 1996-12-20 1998-07-02 Magainin Pharmaceuticals Inc. A method for diagnosis and treatment of inflammatory bowel diseases including crohn's disease and chronic ulcerative colitis
WO1998047516A1 (en) * 1997-04-17 1998-10-29 Prendergast Patrick T Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US6001651A (en) * 1998-03-20 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of LFA-3
DE69914932T2 (de) * 1998-10-20 2004-12-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
RU2140283C1 (ru) * 1998-12-15 1999-10-27 Товарищество с ограниченной ответственностью "Биотех" Фармацевтический препарат на основе интерлейкина-2 (варианты)
MXPA01008142A (es) 1999-02-10 2003-07-21 Welfide Corp Compuestos de amida, y uso medicinal de los mismos.
EP2295968B1 (de) * 1999-12-03 2012-09-19 Baxter International Inc. Test für Pyrogenizität zum Gebrauch in Verbindung mit automatisierten Immunoassay-Systemen
WO2001074388A1 (en) * 2000-03-31 2001-10-11 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
EP1284747A2 (de) 2000-05-12 2003-02-26 Beth Israel Deaconess Medical Center, Inc. Zusammensetzungen und verfahren zur erzielung einer immunsuppression
RU2196605C2 (ru) * 2000-12-07 2003-01-20 Санкт-Петербургский научно-исследовательский институт эпидемиологии и микробиологии им. Пастера Способ получения растворимых конъюгатов биологически активных веществ
RU2202363C2 (ru) * 2001-04-09 2003-04-20 Ершов Феликс Иванович Способ определения чувствительности живого организма и/или его клеток к воздействию вещества, поля или комбинации веществ и/или полей
US20040197304A1 (en) * 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
AR046833A1 (es) * 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
PE20060560A1 (es) 2004-08-03 2006-06-27 Novartis Ag Anticuerpos de interleucina-4 humana
EP2261323A1 (de) 2005-05-31 2010-12-15 The Iams Company Probiotische Katzen-Laktobazillen
AU2006253007B2 (en) 2005-05-31 2012-12-20 Alimentary Health Ltd Feline probiotic Bifidobacteria
WO2007039586A1 (en) * 2005-10-03 2007-04-12 Actogenix Nv Use of recombinant yeast strain producing an anti -inflammatory compound in the manufacture of a medicament to treat colitis
EP2066336B1 (de) * 2006-09-28 2012-09-19 Merck Sharp & Dohme Corp. Verwendung von pegyliertem il-10 zur krebsbehandlung
RU2436581C2 (ru) 2007-02-01 2011-12-20 Дзе Иамс Компани Способ уменьшения воспаления и снижения стресса у млекопитающего
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
MX2015014438A (es) * 2013-04-18 2016-05-18 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
EP3010527B1 (de) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Verfahren zur beurteilung der proteinidentität und -stabilität
PL3369435T3 (pl) 2013-07-18 2020-04-30 Xalud Therapeutics, Inc. Kompozycja do leczenia choroby zapalnej stawów
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
KR20180038553A (ko) 2015-08-25 2018-04-16 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
CN114349858B (zh) * 2022-01-26 2022-07-01 优睿赛思(武汉)生物科技有限公司 抗人白介素-10高亲和力兔单克隆抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
ATE116550T1 (de) * 1991-01-16 1995-01-15 Schering Corp Behandlung von neoplastischen krankenheiten mit interleukin-10.
GB9207732D0 (en) * 1992-04-06 1992-05-27 Isis Innovation Wound repair

Also Published As

Publication number Publication date
CA2142861C (en) 2000-08-15
SK21195A3 (en) 1996-10-02
DE69316921D1 (de) 1998-03-12
HK1004326A1 (en) 1998-11-20
EP0671933A1 (de) 1995-09-20
IL106725A0 (en) 1993-12-08
EP0801951A2 (de) 1997-10-22
HU220103B (hu) 2001-10-28
WO1994004180A3 (en) 1994-06-09
DK0671933T3 (da) 1998-09-23
KR0170037B1 (ko) 1999-02-01
PL307566A1 (en) 1995-05-29
JP3494647B2 (ja) 2004-02-09
AU5010893A (en) 1994-03-15
FI950697A7 (fi) 1995-04-07
FI950697L (fi) 1995-04-07
JPH08500362A (ja) 1996-01-16
MX9305054A (es) 1994-02-28
TW243415B (de) 1995-03-21
CZ44195A3 (en) 1995-10-18
FI950697A0 (fi) 1995-02-16
ES2111769T3 (es) 1998-03-16
IL106725A (en) 2000-12-06
CN1090204A (zh) 1994-08-03
EP0801951A3 (de) 1998-05-20
GR3026635T3 (en) 1998-07-31
CZ283488B6 (cs) 1998-04-15
EP0671933B1 (de) 1998-02-04
AU680628B2 (en) 1997-08-07
HUT70976A (en) 1995-11-28
RU2120802C1 (ru) 1998-10-27
MY111402A (en) 2000-04-29
KR950702841A (ko) 1995-08-23
WO1994004180A2 (en) 1994-03-03
DE69316921T2 (de) 1998-06-04
RU95108330A (ru) 1996-11-27
CA2142861A1 (en) 1994-03-03
HU9500467D0 (en) 1995-04-28

Similar Documents

Publication Publication Date Title
ATE162947T1 (de) Neue verwendungen für il-10
HUT67742A (en) Phosphono-oxymethyl-ethers of taxane derivatives
FI940464A0 (fi) Hartsikoostumus
ATE184789T1 (de) Verwendung von carnosolsäure wegen seiner anticarcinogenen und antiviralen eigenschaften
FR2692755B1 (fr) Composition antimicrobienne.
NL194084B (nl) Roeten alsmede rubbersamenstellingen met dergelijke roeten.
BG102215A (en) Compounds and pharmaceutical compositions containing them
FI942444A0 (fi) Terahydropyraanijohdannaisia
BG103968A (en) Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity
DE3889197D1 (de) Klebstoff-Zusammensetzungen und diese Zusammensetzungen enthaltende Laminate.
DE68901060D1 (de) Biozide zusammensetzungen fuer industriestoffe.
MY128260A (en) Cyclopentane-and-pentene-b-amino acids
DE69114184D1 (de) Harzzusammensetzung für Grundierung und Grundierungsmittel davon.
DE59109007D1 (de) Zusammensetzung zur Regulierung der Darmflora
FI923751A0 (fi) Hexahydrobenso/f/kinolinoner.
DE69313158D1 (de) Kontrastzusammensetzung für M.R.I. des Gastrointestinaltraktes
DE3863687D1 (de) Tinten-zusammensetzungen und deren zubereitung.
FI914156A0 (fi) Kompositioner.
DE3872764D1 (de) Tinten-zusammensetzungen und deren zubereitung.
DE69012630D1 (de) Mittel gegen Ratten.
DE69204141D1 (de) Schutzmutter für Betätigungsknopf.
IT1263170B (it) Composizione antiemorroidale
DE69003521D1 (de) Schmiermittelzusammensetzung und ihre Herstellung.
MX9203089A (es) Composicion para el tratamiento de esquisofrenia.
NO894231D0 (no) Belegningspreparat.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee